immutep (asx:imm) - webinar presentation
Published 7 months ago • 68 plays • Length 16:06Download video MP4
Download video MP3
Similar videos
-
6:25
immutep (asx:imm) discusses a transformative year for lag-3 therapies
-
3:33
immutep (asx:imm) reports positive trial data
-
1:14:06
immutep (asx:imm) sitc 2021 results - management update
-
0:27
a431 cells under hypoxic condition
-
0:27
a431 cells under hypoxic condition
-
2:04
acquired resistance to osimertinib in t790m-positive nsclc
-
3:17
ziftomenib: mechanism of action and promising results in patients with kmt2ar or npm1m aml
-
1:16
mechanisms of resistance to the tki asciminib in cml
-
21:21
biotech unlocked - immutep asx:imm
-
0:42
负离子发生器模块 ionissimo™ mhm3、mhm4系列的除pm2.5效果验证实验 ―单独的负离子发生器―
-
19:07
042 - biotech m&as accelerate. immu's adc shakes up breast cancer!
-
41:48
xmap intelliflex® and immunoassay innovations: tools to advance immuno-oncology research
-
3:23
flt3 and idh1/2 inhibitors
-
3:28
bax-mediated bh3 mimetic resistance in aml
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
3:20
immedia multiglide spu - how to turn from supine to prone
-
2:30
impassion130: immunotherapy for tnbc
-
5:16
ixazomib vs placebo maintenance for ndmm pts not undergoing asct: the phase iii tourmaline-mm4 trial
-
3:32
rapid recommendation update from asco for stage ib-iiia nsclc
-
0:13
omnitest 3 control solution 2 x 3 5ml 9332768g
-
2:08
ixazomib plus chemotherapy for aml & all
-
9:54
pi3k inhibition in breast cancer